Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T, Ko R, Mori K, Kato M, Yagishita S, Kanemaru R, Honma Y, Shibayama R, Koyama R, Shimada N, Takahashi K. Shukuya T, et al. Among authors: shibayama r. Cancer Chemother Pharmacol. 2015 Oct;76(4):771-6. doi: 10.1007/s00280-015-2843-3. Epub 2015 Aug 11. Cancer Chemother Pharmacol. 2015. PMID: 26259641 Clinical Trial.
Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
Nakamura K, Kato M, Shukuya T, Mori K, Sekimoto Y, Ihara H, Kanemaru R, Ko R, Shibayama R, Tajima K, Koyama R, Shimada N, Nagashima O, Takahashi F, Sasaki S, Takahashi K. Nakamura K, et al. Among authors: shibayama r. BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6. BMC Cancer. 2017. PMID: 28464801 Free PMC article.
Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Miyashita Y, et al. Among authors: shibayama r. Thorac Cancer. 2021 Feb;12(3):329-338. doi: 10.1111/1759-7714.13742. Epub 2020 Nov 21. Thorac Cancer. 2021. PMID: 33219754 Free PMC article.
High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
Sumiyoshi I, Okabe T, Togo S, Takagi H, Motomura H, Ochi Y, Shimada N, Haraguchi M, Shibayama R, Fujimoto Y, Watanabe J, Iwai M, Kadoya K, Iwakami SI, Takahashi K. Sumiyoshi I, et al. Among authors: shibayama r. J Transl Med. 2021 Feb 28;19(1):92. doi: 10.1186/s12967-021-02761-1. J Transl Med. 2021. PMID: 33639962 Free PMC article.
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
Shimamura SS, Shukuya T, Asao T, Hayakawa D, Kurokawa K, Xu S, Miura K, Mitsuishi Y, Tajima K, Shibayama R, Shimada N, Takahashi F, Takahashi K. Shimamura SS, et al. Among authors: shibayama r. BMC Cancer. 2022 Mar 25;22(1):323. doi: 10.1186/s12885-022-09421-7. BMC Cancer. 2022. PMID: 35337281 Free PMC article.
Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.
Kurokawa K, Mitsuishi Y, Shimada N, Kawakami Y, Miura K, Miyawaki T, Asao T, Ko R, Shukuya T, Shibayama R, Nojiri S, Takahashi K. Kurokawa K, et al. Among authors: shibayama r. BMC Cancer. 2022 Oct 6;22(1):1047. doi: 10.1186/s12885-022-10133-1. BMC Cancer. 2022. PMID: 36203123 Free PMC article.
27 results